United And Divided: Natco's Patent Challenge On Revlimid Leads Dr. Reddy's To Up Its Pitch
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Natco Pharma's patent challenge earlier this month over Celgene's blockbuster multiple myeloma drug Revlimid (lenalidomide) has led India's Dr. Reddy's Labs to fast-track its own development of the product, which was brought under a restricted distribution plan by U.S. FDA due to its risky profile